ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: SA-PO1200

Serum Amyloid A1 Damages the Peritubular Capillary Network and Promotes Kidney Fibrosis

Session Information

  • CKD: Mechanisms - 3
    October 26, 2024 | Location: Exhibit Hall, Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: CKD (Non-Dialysis)

  • 2303 CKD (Non-Dialysis): Mechanisms

Authors

  • Xiang, Yadie, State Key Laboratory of Organ Failure Research, National Clinical Research Center of Kidney Disease, Renal Division, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China, Guangzhou, Guangdong, China
  • Fu, Haiyan, State Key Laboratory of Organ Failure Research, National Clinical Research Center of Kidney Disease, Renal Division, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China, Guangzhou, Guangdong, China
Background

The deterioration of the peritubular capillary network causes renal tissue ischemia and hypoxia, accelerating chronic kidney disease (CKD). Finding ways to mitigate endothelial cell injury and restore capillary density has been a persistent challenge. This project examines the pathological role and molecular mechanisms of serum amyloid A1 (SAA1), identified by our team as a kidney injury-associated molecule. Using multi-omics analysis and traditional biological experiments, we study SAA1 in CKD patients, mouse models, and in vitro endothelial cell injury models. Our goal is to deepen understanding of CKD pathogenesis, identify therapeutic targets, and develop effective prevention and treatment strategies.

Methods

Proteomic analysis of renal tissue post-ischemia/reperfusion injury (IRI) in mice identified molecules driving renal fibrosis, validated in CKD mouse models and patient biopsy specimens. Gene knockout mice were used in CKD models induced by IRI or unilateral ureteral obstruction (UUO). We employed histology, pathology, immunology, biochemistry, and molecular biology to study expression characteristics and damage effects. In vitro, transcriptome sequencing and traditional experiments elucidated molecular mechanisms in an endothelial cell injury model.

Results

Proteomic analysis of renal tissue post-ischemia/reperfusion injury (IRI) in mice identified molecules driving renal fibrosis, validated in CKD mouse models and patient biopsy specimens. Gene knockout mice were used in CKD models induced by IRI or unilateral ureteral obstruction (UUO). We employed histology, pathology, immunology, biochemistry, and molecular biology to study expression characteristics and damage effects. In vitro, transcriptome sequencing and traditional experiments elucidated molecular mechanisms in an endothelial cell injury model.

Conclusion

SAA1 is critical in renal fibrosis development, causing endothelial cell damage, increasing vascular permeability, disrupting capillary integrity, exacerbating renal ischemia and hypoxia, and accelerating fibrosis via the CD36/JNK pathway. Targeting SAA1 significantly improves renal microcirculation and delays CKD progression. SAA1 vaccination shows promise as an innovative CKD therapy.

Funding

  • Government Support – Non-U.S.